The Journal of Thoracic and Cardiovascular Surgery
Volume 125, Issue 1 , Pages 184-190 , January 2003

Does aprotinin influence the inflammatory response to cardiopulmonary bypass in patients?

Presented in part at the Annual Meeting of the American Society of Anesthesiologists, Orlando, Fla, October 1998.

Received 16 April 2001 ,Revised 25 July 2001 ,Accepted 15 November 2001.

References 

  1. Menasche P. The inflammatory response to cardiopulmonary bypass and its impact on postoperative myocardial function. Curr Opin Cardiol. 1995;10:597–604
  2. Mojcik CF, Levy JH. Aprotinin and the systemic inflammatory response after cardiopulmonary bypass. Ann Thorac Surg. 2001;71:745–754
  3. Wan S, Leclerc JL, Vincent JL. Inflammatory response to cardiopulmonary bypass: mechanisms involved and possible therapeutic strategies. Chest. 1997;112:676–692
  4. Royston D. Systemic inflammatory responses to surgery with cardiopulmonary bypass. Perfusion. 1996;11:177–189
  5. Tabardel Y, Duchateau J, Schmartz D, Marécaux G, Shahla M, Barvais L, et al.  Corticosteroids increase blood interleukin-10 levels during cardiopulmonary bypass in men. Surgery. 1996;119:76–80
  6. Hennein HA, Ebba H, Rodriguez JL, Merrick SH, Keith FM, Bronstein MH, et al.  Relationship of the proinflammatory cytokines to myocardial ischemia and dysfunction after uncomplicated coronary revascularization. J Thorac Cardiovasc Surg. 1994;108:626–635
  7. Engelman RM, Rousou JA, Flack JE, Deaton DW, Kalfin R, Das DK. Influence of steroids on complement and cytokine generation after cardiopulmonary bypass. Ann Thorac Surg. 1995;60:801–804
  8. Bando K, Pillai R, Cameron DE, Brawn JD, Winkelstein JA, Hutchins GM, et al.  Leukocyte depletion ameliorates free radical-mediated lung injury after cardiopulmonary bypass. J Thorac Cardiovasc Surg. 1990;99:873–877
  9. Baufreton C, Le Besnerais P, Jansen P, Mazzucotelli JP, Wildevuur CR, Loisance DY. Clinical outcome after coronary surgery with heparin-coated extracorporeal circuits for cardiopulmonary bypass. Perfusion. 1996;11:437–443
  10. Wan S, Izzat MB, Lee TW, Wan IY, Tang NL, Yim AP. Avoiding cardiopulmonary bypass in multivessel CABG reduces cytokine response and myocardial injury. Ann Thorac Surg. 1999;68:52–56
  11. Wei M, Kuukasjarvi P, Laurikka J, Kaukinen S, Iisalo P, Laine S, et al.  Cytokine responses and myocardial injury in coronary artery bypass grafting. Scand J Clin Lab Invest. 2001;61:161–166
  12. Westaby S. Aprotinin in perspective. Ann Thorac Surg. 1993;55:1033–1041
  13. Wachtfogel YT, Kucich U, Hack CE, Niewiarowski S, Colman RW, Edmunds LH. Aprotinin inhibits the contact, neutrophil, and platelet activation systems during simulated extracorporeal perfusion. J Thorac Cardiovasc Surg. 1993;106:1–9
  14. Siebeck M, Fink E, Weipert J, Jochum M, Fritz H, Spannagl M, et al.  Inhibition of plasma kallikrein with aprotinin in porcine endotoxin shock. J Trauma. 1993;34:193–198
  15. Dwenger A, Remmers D, Grotz M, Pape HC, Gruner A, Scharff H, et al.  Aprotinin prevents the development of the trauma-induced multiple organ failure in a chronic sheep model. Eur J Clin Chem Clin Biochem. 1996;34:207–214
  16. Royston D. Coagulation in cardiac surgery. Adv Card Surg. 1996;8:19–45
  17. Fritz H, Wunderer G. Biochemistry and applications of aprotinin, the kallikrein inhibitor from bovine organs. Arzneimittelforschung. 1983;33:479–494
  18. Soeparwata R, Hartman AR, Frerichmann U, Stefano GB, Scheld HH, Bilfinger TV. Aprotinin diminishes inflammatory processes. Int J Cardiol. 1996;53(suppl):S55–S63
  19. Gilliland HE, Armstrong MA, Uprichard S, Clarke G, McMurray TJ. The effect of aprotinin on interleukin-8 concentration and leukocyte adhesion molecule expression in an isolated cardiopulmonary bypass system. Anaesthesia. 1999;54:427–433
  20. Ali M, Becket J, Brannan J, Fleming J, Taylor KM. The effect of high dose aprotinin therapy on the systemic inflammatory response in a porcine model of cardiopulmonary bypass. Perfusion. 1996;11:278–280
  21. Hill GE, Alonso A, Spurzem JR, Stammers AH, Robbins RA. Aprotinin and methylprednisolone equally blunt cardiopulmonary bypass-induced inflammation in humans. J Thorac Cardiovasc Surg. 1995;110:1658–1662
  22. Royston D. Preventing the inflammatory response to open-heart surgery: the role of aprotinin and other protease inhibitors. Int J Cardiol. 1996;53(suppl):S11–S37
  23. Alonso A, Whitten CW, Hill GE. Pump prime only aprotinin inhibits cardiopulmonary bypass-induced neutrophil CD11b up-regulation. Ann Thorac Surg. 1999;67:392–395
  24. Ashraf S, Tian Y, Cowan D, Nair U, Chatrath R, Saunders NR, et al.  “Low-dose” aprotinin modifies hemostasis but not proinflammatory cytokine release. Ann Thorac Surg. 1997;63:68–73
  25. Barvais L. Predictive accuracy of intravenous anesthetic drugs. Acta Anaesthesiol Belg. 1997;48:217–221
  26. Barvais L, D'Hollander AA, Cantraine F, Coussaert E, Diamon G. Predictive accuracy of midazolam in adult patients scheduled for coronary surgery. J Clin Anesth. 1994;6:297–302
  27. Royston D. Aprotinin prevents bleeding and has effects on platelets and fibrinolysis. J Cardiothorac Vasc Anesth. 1991;5:18–23
  28. Richter JA, Meisner H, Tassani P, Barankay A, Dietrich W, Braun SL. Drew-Anderson technique attenuates systemic inflammatory response syndrome and improves respiratory function after coronary artery bypass grafting. Ann Thorac Surg. 2000;69:77–83
  29. Tassani P, Richter JA, Barankay A, Braun SL, Haehnel C, Spaeth P, et al.  Does high-dose methylprednisolone in aprotinin-treated patients attenuate the systemic inflammatory response during coronary artery bypass grafting procedures?. J Cardiothorac Vasc Anesth. 1999;13:165–172
  30. Appoloni O, Dupont E, Andrien M, Duchateau J, Vincent JL. Association of TNF2, a TNFα promoter polymorphism, with plasma TNFα levels and mortality in septic shock. Am J Med. 2001;110:486–488
  31. Martinez-Pellus AE, Merino P, Bru M, Canovas J, Seller G, Sapina J, et al.  Endogenous endotoxemia of intestinal origin during cardiopulmonary bypass. Role of type of flow and protective effect of selective digestive decontamination. Intensive Care Med. 1997;23:1251–1257
  32. Ohri SK. Systemic inflammatory response and the splanchnic bed in cardiopulmonary bypass. Perfusion. 1996;11:200–212
  33. Defraigne JO, Pincemail J, Larbuisson R, Blaffart F, Limet R. Cytokine release and neutrophil activation are not prevented by heparin-coated circuits and aprotinin administration. Ann Thorac Surg. 2000;69:1084–1091
  34. Hill GE, Pohorecki R, Alonso A, Rennard SI, Robbins RA. Aprotinin reduces interleukin-8 production and lung neutrophil accumulation after cardiopulmonary bypass. Anesth Analg. 1996;83:696–700
  35. Gott JP, Cooper WA, Schmidt FE, Brown WM, Wright CE, Merlino JD, et al.  Modifying risk for extracorporeal circulation: trial of four antiinflammatory strategies. Ann Thorac Surg. 1998;66:747–753
  36. Dehoux M, Philip I, Chollet-Martin S, Boutten A, Hvass U, Desmonts JM, et al.  Early production of interleukin-10 during normothermic cardiopulmonary bypass. J Thorac Cardiovasc Surg. 1995;110:286–287
  37. Hill GE, Diego RP, Stammers AH, Huffman SM, Pohorecki R. Aprotinin enhances the endogenous release of interleukin-10 after cardiac operations. Ann Thorac Surg. 1998;65:66–69
  38. Steinberg JB, Kapelanski DP, Olson JD, Weiler JM. Cytokine and complement levels in patients undergoing cardiopulmonary bypass. J Thorac Cardiovasc Surg. 1993;106:1008–1016
  39. Murkin JM. Cardiopulmonary bypass and the inflammatory response: a role for serine protease inhibitors?. J Cardiothorac Vasc Anesth. 1997;11:19–23
  40. Royston D. High-dose aprotinin therapy: a review of the first five years' experience. J Cardiothorac Vasc Anesth. 1992;6:76–100
  41. Seghaye MC, Duchateau J, Grabitz RG, Mertes J, Marcus C, Buro K, et al.  Histamine liberation related to cardiopulmonary bypass in children: Possible relation to transient postoperative arrhythmias. J Thorac Cardiovasc Surg. 1996;111:971–981
  42. Levi-Schaffer F, Shalit M. Differential release of histamine and prostaglandin D2 in rat peritoneal mast cells activated with peptides. Int Arch Allergy Appl Immunol. 1989;90:352–357

☆ This work was supported by a grant from Bayer, Leverkusen, Germany.

☆☆ Address for reprints: Denis Schmartz, MD, Department of Anesthesiology, Erasme University Hospital, 808 route de Lennik, B-1070 Brussels, Belgium (E-mail: denis.schmartz@ulb.ac.be).

PII: S0022-5223(02)73311-4

doi: 10.1067/mtc.2003.64

The Journal of Thoracic and Cardiovascular Surgery
Volume 125, Issue 1 , Pages 184-190 , January 2003

Article Tools

* Image Usage & Resolution